Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Simonetta Viviani

Showing results (81-90 of 111) with videos related to

Pageof 12
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 25, 2007
Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish studyAndrea Gallamini, Martin Hutchings, Luigi Rigacci, et al.
Haematologica|September 16, 2017
Secondary malignant neoplasms, progression-free survival and overall survival in patients treated for Hodgkin lymphoma: a systematic review and meta-analysis of randomized clinical trialsDennis A Eichenauer, Ingrid Becker, Ina Monsef, et al.
Blood|March 12, 2010
Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective study based on the time of HLA typing and donor availabilityBarbara Sarina, Luca Castagna, Lucia Farina, et al.
Hematological Oncology|December 19, 2022
Predictive value on advance hodgkin lymphoma treatment outcome of end-of treatment FDG PET/CT in the HD0607 clinical trialAlberto Biggi, Stephane Chauvie, Federico Fallanca, et al.
British Journal of Haematology|December 21, 2010
Early chemotherapy intensification with BEACOPP in advanced-stage Hodgkin lymphoma patients with a interim-PET positive after two ABVD coursesAndrea Gallamini, Caterina Patti, Simonetta Viviani, et al.
Leukemia & Lymphoma|September 17, 2004
Elevated serum levels of IL-10 are associated with inferior progression-free survival in patients with Hodgkin's disease treated with radiotherapyCarlo Visco, Theodoros P Vassilakopoulos, Kay Oliver Kliche, et al.
Human Vaccines & Immunotherapeutics|October 21, 2022
The neutralizing response to SARS-CoV-2 Omicron variants BA.1 and BA.2 in COVID-19 patients and homologous and heterologous vaccineesFrancesca Dapporto, Margherita Leonardi, Claudia Maria Trombetta, et al.
Communications Biology|September 2, 2022
Immune response to SARS-CoV-2 Omicron variant in patients and vaccinees following homologous and heterologous vaccinationsClaudia Maria Trombetta, Giulia Piccini, Giulio Pierleoni, et al.
The New England Journal of Medicine|July 22, 2011
ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is plannedSimonetta Viviani, Pier Luigi Zinzani, Alessandro Rambaldi, et al.
Leukemia & Lymphoma|January 2, 2024
High-dose chemotherapy and autologous stem cell transplant as first salvage treatment for relapsed or refractory Hodgkin Lymphoma in the era of PET-adapted strategiesSimonetta Viviani, Anna Vanazzi, Samuele Frassoni, et al.
Pageof 12

Showing results (81-90 of 111) with videos related to

Sort By:
Pageof 12
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 25, 2007
Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish studyAndrea Gallamini, Martin Hutchings, Luigi Rigacci, et al.
Haematologica|September 16, 2017
Secondary malignant neoplasms, progression-free survival and overall survival in patients treated for Hodgkin lymphoma: a systematic review and meta-analysis of randomized clinical trialsDennis A Eichenauer, Ingrid Becker, Ina Monsef, et al.
Blood|March 12, 2010
Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective study based on the time of HLA typing and donor availabilityBarbara Sarina, Luca Castagna, Lucia Farina, et al.
Hematological Oncology|December 19, 2022
Predictive value on advance hodgkin lymphoma treatment outcome of end-of treatment FDG PET/CT in the HD0607 clinical trialAlberto Biggi, Stephane Chauvie, Federico Fallanca, et al.
British Journal of Haematology|December 21, 2010
Early chemotherapy intensification with BEACOPP in advanced-stage Hodgkin lymphoma patients with a interim-PET positive after two ABVD coursesAndrea Gallamini, Caterina Patti, Simonetta Viviani, et al.
Leukemia & Lymphoma|September 17, 2004
Elevated serum levels of IL-10 are associated with inferior progression-free survival in patients with Hodgkin's disease treated with radiotherapyCarlo Visco, Theodoros P Vassilakopoulos, Kay Oliver Kliche, et al.
Human Vaccines & Immunotherapeutics|October 21, 2022
The neutralizing response to SARS-CoV-2 Omicron variants BA.1 and BA.2 in COVID-19 patients and homologous and heterologous vaccineesFrancesca Dapporto, Margherita Leonardi, Claudia Maria Trombetta, et al.
Communications Biology|September 2, 2022
Immune response to SARS-CoV-2 Omicron variant in patients and vaccinees following homologous and heterologous vaccinationsClaudia Maria Trombetta, Giulia Piccini, Giulio Pierleoni, et al.
The New England Journal of Medicine|July 22, 2011
ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is plannedSimonetta Viviani, Pier Luigi Zinzani, Alessandro Rambaldi, et al.
Leukemia & Lymphoma|January 2, 2024
High-dose chemotherapy and autologous stem cell transplant as first salvage treatment for relapsed or refractory Hodgkin Lymphoma in the era of PET-adapted strategiesSimonetta Viviani, Anna Vanazzi, Samuele Frassoni, et al.
Pageof 12